The evaluation of noncytotoxic agents for
the treatment of epithelial ovarian cancer
has produced encouraging findings in
recent months, which has led to the approval of
new agents with novel mechanisms of action
and continuing studies into many more potential
Agustin A. Garcia, MD, associate professor of medicine, Keck School of Medicine of the University of Southern California, discusses the future role of PARP inhibitors for patients with ovarian cancer and breast cancer.
Agustin A. Garcia, MD, from the Keck School of Medicine of the University of Southern California, discusses a phase I trial analyzing the PARP inhibitor veliparib (ABT-888) in patients with breast cancer.